Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 30, 2007

UCLA Researchers Discover Genes Linked to Lymphoma

  • Researchers at the University of California Los Angeles identified genes that, when inactivated, help cause B-cell non-Hodgkin's lymphoma (NHL). These genetic defects may also be involved in promoting the formation of other cancers since they can inactivate normal tumor-suppressing gene activities in a range of cell types.

    The team used genetically engineered mice to accurately mimic human B-cell cancers. They had previously identified frequent genetic abnormalities in cancer cells from NHL patients—namely defects in the TCL1 gene—and showed that TCL1 abnormalities can cause NHL in mice when accompanied by additional genetic defects. Now, they have found some of these cancer collaborators.

    Michael Teitell, M.D., Ph.D., and his team used restriction landmark genomic scanning (RLGS) to find genes that work with abnormal TCL1 to promote lymphoma formation. These genes are inactivated in lymphomas by DNA hypermethylation.

    The research, published in the January 29, 2007, issue of Oncogene, may help in the development of new targeted drugs for NHL patients.The study was funded by The Leukemia & Lymphoma Society.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »